RecruitingPhase 3NCT06962800
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Studying Primary membranous glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biogen
- Principal Investigator
- Medical DirectorBiogen
- Intervention
- Felzartamab(drug)
- Enrollment
- 180 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- Apogee Clinical Research, LLC, Huntsville, Alabama, United States
- The Nephrology Group, Inc. - Fresno, Fresno, California, United States
- Academic Medical Research Institute, Los Angeles, California, United States
- UCSF Medical Center, San Francisco, California, United States
- Henry Ford Hospital- A-Basement Research Pharmacy, Detroit, Michigan, United States
- Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS, Pontiac, Michigan, United States
- James J Peters Veterans Administration Medical Center - NAVREF - PPDS, The Bronx, New York, United States
- ECU Physicians Nephrology and Hypertension, Greenville, North Carolina, United States
- Knoxville Kidney Center, PLLC, Knoxville, Tennessee, United States
- Nephrotex Research Group, Dallas, Texas, United States
- University of Texas Medical Branch, League City, Texas, United States
- Organización Médica de Investigación, Buenos Aires, Argentina
- CINME S.A. - Centro de Investigaciones Metabólicas, Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Buenos Aires, Argentina
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06962800 on ClinicalTrials.govOther trials for Primary membranous glomerulonephritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07289763Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2, PHASE3NCT07204275A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Vertex Pharmaceuticals Incorporated
- RECRUITINGPHASE2NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)Alexion Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT07096843A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyClimb Bio, Inc.
- RECRUITINGPHASE1NCT06982729Study of YK012 in Primary Membranous NephropathyExcyte Biopharma Ltd
- RECRUITINGNCT06242327An Outcome Analysis of Primary Membranous NephropathyMario Negri Institute for Pharmacological Research
- ACTIVE NOT RECRUITINGPHASE2NCT06642909A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous NephropathyBioRay Pharmaceutical Co., Ltd.
- RECRUITINGNCT06893328A Real World Study About PMNWei Chen